by Pasteur Institute
Graphical Abstract. Credit: Cell Reports Medicine (2023). DOI: 10.1016/j.xcrm.2023.101167
Pneumonia is an infection of the lung alveoli caused by bacteria, viruses or fungi. It is one of the leading causes of morbidity and mortality worldwide, representing a clinical and economic burden and a global public health problem. The microbial ecosystem (or microbiome) of the human respiratory tract colonizes different niches.
The respiratory tract microbiome is of interest to scientists as it contributes to human health by stimulating the immune system and protecting against infection by pathogens. Scientists from the Institut Pasteur and the CNRS have demonstrated that the microbiome composition, pathogen load and clinical interventions influence the severity of bacterial pneumonia caused by Legionella pneumophila.
The results were published in the journal Cell Reports Medicine.
In this study, scientists from the Biology of Intracellular Bacteria Unit, led by Carmen Buchrieser at the Institut Pasteur, in collaboration with Sophie Jarraud, Head of the National Reference Center for Legionella in Lyon, analyzed the diversity and composition of the respiratory tract microbiome (bacteria, archaea, fungi and protozoa) in patients with pneumonia caused by the intracellular bacterial pathogen Legionella pneumophila for their entire hospitalization period.
L. pneumophila is responsible for a severe pneumonia known as Legionnaires’ disease, which can be contracted by inhaling contaminated aerosols from artificial water sources such as showers, hot tubs or air conditioning systems. The fatality rate for Legionnaires’ disease varies from 5% to 40% depending on the clinical context and the region. Risk factors are old age, pre-existing lung conditions, smoking and immunosuppression, and around two-thirds of reported cases occur in men.
Confirmed cases of Legionnaires’ disease in the European Union went from 4,693 cases in 2005 to 10,004 cases in 2021, an increase of 113%. One of the reasons for this sharp rise may be climate change, with higher water temperatures and more frequent and intense floods that allow Legionella to replicate more rapidly and to access human environments.
The team of scientists combined high-throughput bacterial, archaeal and fungal marker gene sequencing with a quantification approach to characterize how the respiratory tract microbiome developed in patients over the course of infection and as a result of hospital-related interventions (such as mechanical ventilation and administration of antibiotics).
A unique cohort of 38 hospitalized patients with pneumonia caused by Legionella pneumophila was analyzed.
“We discovered complex microbiome dynamics, where commensal and pathogenic microorganisms coexist, and the equilibrium among their abundance drives the microbiome to recovery or dysbiosis,” explains Carmen Buchrieser, lead author of the study and Head of the Institut Pasteur’s Biology of Intracellular Bacteria Unit. The scientists observed that early in hospitalization, microbiome diversity decreased and the pathogen L. pneumophila was killed by the antibiotic treatment.
But the empty niche was soon occupied by other opportunistic species, often resistant to antimicrobials—a factor that should be considered in prevention strategies for secondary infections. The respiratory tract microbiomes with the highest bacterial and fungal loads also showed lower diversity and pathogen enrichment, indicating that high biomass could be a biomarker for secondary and/or co-infections.
Finally, the scientists showed that Legionella biomass correlates with disease severity and comorbidities, suggesting that pathogen quantification should be included in patient monitoring. Clinical interventions such as mechanical ventilation or administration of certain types of antibiotics influence the microbiome composition and therefore also disease outcome.
“In this study we also discovered that fungi, archaea and protozoa may be resident and not merely transitory in the respiratory tract of hospitalized patients and that they might contribute to pneumonia progression. This requires further investigation. Our research therefore shows that the interaction between respiratory tract microbiome equilibrium, pathogen load dynamics and clinical interventions plays a crucial role in the recovery of patients with pneumonia,” concludes Carmen Buchrieser.
More information: Ana Elena Pérez-Cobas et al, The respiratory tract microbiome, the pathogen load, and clinical interventions define severity of bacterial pneumonia, Cell Reports Medicine (2023). DOI: 10.1016/j.xcrm.2023.101167
Journal information: Cell Reports Medicine
Provided by Pasteur Institute
More information: Ana Elena Pérez-Cobas et al, The respiratory tract microbiome, the pathogen load, and clinical interventions define severity of bacterial pneumonia, Cell Reports Medicine (2023). DOI: 10.1016/j.xcrm.2023.101167
Journal information: Cell Reports Medicine
Provided by Pasteur Institute
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Optional (only if you want to be contacted back)
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
We keep our content available to everyone. Consider supporting Science X’s mission by getting a premium account.
This article has been reviewed according to Science X’s editorial process and policies. Editors have highlighted the following attributes while ensuring the content’s credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
43 shares
How the respiratory tract microbiome influences the severity of bacterial pneumonia
Note:
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Tech Xplore in any form.
About
Medical Xpress is a web-based medical and health news service that is part of the renowned Science X network. Based on the years of experience as a Phys.org medical research channel, started in April 2011, Medical Xpress became a separate website.
Medical Xpress is a part of Science X network. With global reach of over 5 million monthly readers and featuring dedicated websites for hard sciences, technology, smedical research and health news, the Science X network is one of the largest online communities for science-minded people.
Science X Account
Forgot Password?
Not a member? Sign up.
Identify the news topics you want to see and prioritize an order.
Science X Daily and the Weekly Email Newsletter are free features that allow you to receive your favorite sci-tech news updates in your email inbox
© Medical Xpress 2011 – 2023 powered by Science X Network
Newsletter
Science X Daily and the Weekly Email Newsletters are free features that allow you to receive your favourite sci-tech news updates.
Please, allow us to send you push notifications with new Alerts.
Your privacy
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.